Sweden · Delayed Price · Currency is SEK Egetis Therapeutics AB Earnings Call Transcripts
Fiscal Year 2026
-
FDA accepted NDA for Emcitate with priority review and a Q4 2026 U.S. launch expected. Q1 revenue grew 9% year-over-year, and SEK 350 million was raised to support commercialization and pipeline expansion. European sales momentum continues despite reimbursement challenges.
-
Emcitate achieved EU approval and is under FDA review, supported by robust mortality and clinical data. U.S. commercialization efforts are ramping up, with significant patient identification and a potential $1M annual price point. Indication expansion and new IP strategies are underway.
-
The CEO shared insights on rare disease drug development, highlighting progress in diagnosis, regulatory milestones, and commercialization strategies. Emcitate's approval in Europe and pending U.S. launch mark significant achievements, with further pipeline expansion and profitability expected within a year of U.S. entry.
Fiscal Year 2025
-
Emcitate revenue grew 40% year-over-year to SEK 62.4 million, driven by EU launch and expanded access. U.S. NDA submission completed, with FDA decision expected in September 2026 and launch preparations underway. Patient identification in the U.S. surpassed 140, with further growth anticipated.
-
FDA Breakthrough Therapy designation and positive ReTRIEVE study results support Triac's NDA submission for MCT8 deficiency, with U.S. launch preparations underway. Revenue and cash position improved year-over-year, bolstered by a SEK 172 million rights issue.
-
The ReTRIACt study in MCT8 deficiency showed a significant difference in serum T3 changes between placebo and tiratricol, supporting a robust NDA submission. Regulatory milestones are on track, with a rolling submission planned for December 2025 and FDA review expected to complete in Q3 2026.
-
Emcitate, recently approved in Europe for MCT8 deficiency, is advancing toward a US rolling NDA submission, supported by robust clinical and survival data. Early access programs and commercial launches are expanding globally, with future plans for indication expansion into RTH beta.
-
FDA granted rolling NDA review for MCT8, with submission starting December 2025 and review completion expected Q3 2026. The NDA is based on robust clinical data from six sources, and the retried study is now complementary. Ongoing FDA collaboration and legislative updates may impact review timelines.
-
FDA breakthrough therapy designation and Emcitate's commercial launch in Germany mark a pivotal shift to commercialization, with strong early patient conversion and expanding global partnerships. H1 revenues grew year-over-year, but guidance remains withheld due to ongoing EU pricing processes.
-
Full EU approval and imminent German launch of Emcitate mark a major commercial milestone, with U.S. NDA submission planned for 2025 and global expansion underway. Q1 revenues rose to SEK 12.7 million, and cash position improved to SEK 273 million.
-
MCT8 deficiency is a rare, severe disorder with high childhood mortality, but Triac treatment normalizes T3, improves metabolic symptoms, and may reduce mortality by threefold. Neurodevelopmental outcomes remain unchanged, but overall patient well-being improves, and future research may explore prenatal therapy and screening.
Fiscal Year 2024
-
Full European approval of Emcitate marks a shift to commercial stage, with Germany launch set for Q2 2025 and U.S. NDA filing planned for 2025. Revenue declined year-over-year due to prior one-time income, but cash position improved after a major share issue.
-
Key milestones achieved include progress on EU approval for Emcitate, strong survival data, and a $30M share issue. Q3 revenue declined due to order timing, but cash position improved. EMA and U.S. regulatory processes remain on track.
-
Triac Trial II in young children with MCT8 deficiency showed no statistically significant improvement in neurocognitive endpoints versus historical controls, but confirmed significant T3 reduction and a strong safety profile. Regulatory timelines and approval probability remain unchanged.